TY - JOUR T1 - Correction: <em>Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 787 LP - 788 DO - 10.1136/annrheumdis-2017-211388corr1 VL - 77 IS - 5 A2 - , Y1 - 2018/05/01 UR - http://ard.bmj.com/content/77/5/787.abstract N2 - Chamberlain C, Colman PJ, Ranger AM, et al. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann of Rheum Dis 2017;77:1837-44.Since publishing the above article, an error in the … ER -